Jazz Pharmaceuticals plc Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price
Jazz Pharmaceuticals plc (JAZZ) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price of $163.35 per share for the 12-month period ending 2024-12-31, per its 10-K filed 2025-02-26.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice · last filed 2025-02-26
- Jazz Pharmaceuticals plc share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2024 was $163.35, a 21.97% increase from fiscal 2023.
- Jazz Pharmaceuticals plc share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2023 was $133.93, a 3.09% increase from fiscal 2022.
- Jazz Pharmaceuticals plc share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2022 was $129.91, a 6.70% decline from fiscal 2021.
- Jazz Pharmaceuticals plc share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2021 was $139.24, a 1.10% increase from fiscal 2020.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 12 month |
|---|---|
| 2024-12-31 | $163.35 10-K · filed 2025-02-26 |
| 2023-12-31 | $133.93 10-K · filed 2024-02-28 |
| 2022-12-31 | $129.91 10-K · filed 2023-03-01 |
| 2021-12-31 | $139.24 10-K · filed 2022-03-01 |
| 2020-12-31 | $137.73 10-K · filed 2021-02-23 |
| 2019-12-31 | $139.56 10-K · filed 2020-02-25 |
| 2018-12-31 | $139.36 10-K · filed 2019-02-26 |
| 2017-12-31 | $140.04 10-K · filed 2018-02-27 |
| 2016-12-31 | $142.50 10-K · filed 2017-02-28 |
| 2015-12-31 | $118.05 10-K · filed 2016-02-23 |
| 2014-12-31 | $75.08 10-K · filed 2015-02-24 |
| 2013-12-31 | $46.44 10-K · filed 2014-02-25 |
| 2012-12-31 | $34.54 10-K · filed 2013-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |